caerinOf Ip wSeY e siaF00E0 HO-020A0R-16263-703545 RECEIVED OPPT ceIC WONAR 20 Aif11: 43 March 17, 2000 (DAotctun:meSnetctPiroonce8s(s)inCgooCrednitnearto(r7)407) obPT Room G-099 US EPA 401 M Street, SW.

bn Te wt oe an al } `DuPont HaskellLaboratory Disecior,Applied Tox . benTuxicology DuPoat Haskell Laboratory v P.0.Box 50 Elkton Road Newark,Delaware (9714-0050 : Phioge: (302) 366-5259 OS a v Hai kae aa rr ocr 40 220-1559 * Dumcas Control Office (7407) `Room G99 East Tower ATTN: FYT 4OUf0Sf1.icMEevoSftirrPeoeotln,lumSteiWon.ntPPrreovteencttiioonnaAngdeTnocxyics `Washington, D.C. 20460-0001 .

TTT a Specialy Materials 3SuMPCaeunlteMrN 55144-1000 S17 0 Ae226-1717 May 11,2004 TSCA Non-Confidential Information Center (7407T) Office of Pollution Prevention and Toxics (OPPT) EDoPcAkeWteAstR-B2u2il6ding, Room B-146 1301 Constitution Ave., N.W.

STABILITY IN WATER (PHOTOLYSIS) TEST SUBSTANCE Identity: Perfluorooctanesulfonate-potassium salt.

Estrous Cycling and Natural Delivery/Litter Observation Data F1 Estrous Cycling Data, From Data Analysis Presented at EPA on August 30, 2002 a APFO Dose Group (mg/kg/day) 0 1 3 10 30 All 4-Day Cycles 3-5 Day Cycles 14/30 24/30 19/29 26/29 9/30 21/30 15/29 25/29 15/30 27/30 Cycle Length (Days) 2 3 4 5 6 7 8 Mean Cycle Length (Days) S.D. 1 2 75 18 5 1 2 4.3 + 0.8 Incidence of Cycle Length Per Group 0 1 80 16 2 1 0 4.2 0.5 5 7 57 32 5 0 1 4.3 + 0.9 2 5 84 14 3 0 0 4.1 0.6 5 5 86 17 0 0 2 4.1 0.8 Aberrant Cycles b Parental > 4 Days Diest. 2 1 1 4 1 > 3 Days Est. 17 13 15 16 13 F1 > 4 Days Diest. 5 3 3 5 3 > 3 Days Est. 25 25 29 11 14 Distribution of Cycle Status at Start of 21-Day Evaluation Period, F1 P 1 4 1 2 5 E 8 10 11 14 11 M 6 2 2 0 2 D 15 13 16 13 12 Distribution Rats in Estrous at End of 21-Day Evaluation Period, F1 End in Estrous 13 17 18 19 19 Mean Implantations, Liveborn, and Stillborn S.D. per Litter by Group" Parental Litters Implantations Livebom StiUbom 15.3 1.9 14.2 _: 2.2 0.1 0.3 15.6 2.1 14.2 + 2.6 15.2 2.3 13.4 3.6 0.4 1.4 0.2 0.4 F1 Litters 15.6 + 2.0 13.8 3.0 0.1 0.4 15.3 2.0 13.4 3.3 0.2 0.6 Implantations Livebom Stillborn 14.8 3.0 13.6 + 2.9 0.2 0.5 15.8 2.1 13.7 2.4 0.2 0.5 14.7 2.8 13.8 3.0 0.2 0.6 15.0 2.9 13.5 3.1 0.2 0.5 14.5 2.9 13.3 2.8 0.1 0.2 a Original analysis counted cycles from the day following estrous (or proestrous if diestrus followed proestrous without observation of estrous) to the day following the end of the next estrous.

Extraction of Potassium Perfluorooctanesulfonate from Red Blood Cells and Serum for Analysis Using HPLC-Electrospray/Mass Spectrometry DATA REQUIREMENTS Analytical Method Requirements Sean Gallagher ANALYTICAL REPORT DATE June 2, 2003 PERFORMING LABORATORY / TESTING FACILITY 30E3x8ygReesneRaerscehaDrrcihve State College, PA 16801 Phone: 814-272-1039 STUDY SPONSOR 3M Environmental Technology and Safety Services Building 2-3E-09 PO Box 33331 St.

MIN 3131023622 PERFLUOROOCTANESULFONYL FLUORIDE (POSF; T-7661.4) TOXICITY STUDY BY INHALATION ADMINISTRATION TO CD RATS FOR 13 WEEKS FOLLOWED BY A 4 WEEK RECOVERY PERIOD Volume 1 Sponsor. 3M Center, 3M Corporate Toxicology, Building 220-2602, StPaul, MN 55133-3220, USA.

iim EPweuyr an ALIS Pres In AIL-Bosty375 } 3 OL AUS [2 mig: 5 = August9, 2004 VIA E-MAIL = i or Se Derr DocumentControl Office(DCO) IA EI M a 1 EVU1o2S0i1EBgnCvaoiornorRnsomCioengm3tn0a6l6A4Pv70r8eotneec,tion Agency ` A wo At-rio:DockeNo.AR226wdthe FY Dicks ORHEHF THRe RRen Y Subject: ScNoendhSu15b,m3i0s0i3onofAeRnOiniegsDLtOs\Pcrcothatcs 3(0L65OIded Dear iorMadam: TBhUEesieusarsdupLeOeATtsLcatsyeudbwMomeietnkhesndop1w4a,pr2sor0at0naotrToshoososreporLbtees eSorNeoeefPonFenOnnRtw(bLagpO motii pMsio to co h 3co ,w2Se dt0saenAAdTP0FF miionn igof oFFpOA, ing heDec rs poof nr05 CoCAtsmaoeostntiGmrnlovnaemn3sdiMoscerLpooOtaLnnm0isnciooGtmtrtbueisofhn3edMtsss.oionTsthespnmpeolprsnrswghtow ftooPsFiObsALt ObsoLt,msonnitUn orninsg oe f wastey en wattetr ta SScNaonrrptoarootpdueocoivsroinhmnepeaatesooernonn]ofPipaOAunRee,scnsocfrcioccpsnbiagseodieeeemdnps pd eotoe0fs 0ys8Teeocepnremee res AELEEOt ofMhe crFoimmviibmeencrs iunshrurheeiAP,E1UsGHLCOL BesatteehlecDnynngowsoosoo s sm p PmTgS PPoiheeesedmersiryeipoaifovrnBneEhbAoofs,cstieaetsndoemmoDiiourctkiaSuohbropgbiArcRsak.igu3oon3nu8dneoDdrfitihomeuLasntOiidnocsnga aDbnReossOf+AbdueneB dhstecMute ga2ys7, 20e05 eceoroWet nChota,eenngelnm1d rope ot le oor BE 180 ON NIVIN~~ 278 N72.

oppr- 2007 _00(2 _0: November 8, 2004 To: Mary F.

AR226-2286 Frank D Smith "^Sy 05/13/2002 08.-25 AM To: cc: Subject: Catherine A Barton/ABDuPont DuPont Kenneth N Wood/AE/DuPont@DuPont, James F Riley/CL/DuPonlQDuPonl.

AR226-2471 DiiPofti WsshiBpon Woiks P. 0.

AR226-3211 TRADE SECRET Study Title H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Supplement No. 1 Laboratory Project ID: DuPont-2923 AUTHOR: Carol Finlay, B.A.

NORTHERN KENTUCKY OFFICE TAFT, STETTINIUS & HOLLISTER LLP -A R a OR 6 p.1 ~~56",v CLEVELAND, OHIO OFFICE 1717 SUITE 340 3500 BP TOWER 425 WALNUT STREET, SUITE 1800 COVINGTON, KIEVNT4U1C0K 1Y 1-4704 606-331-283 6 200 PUBLIC SQUARE CLEVELAND, OHIO 44114-2302 i~ PP 513-381-2838 216-241-2838 CINCINNATI, OHIO 45202-3957 FAX : 513-381-6613 FAX: 216-241-3707 COLUMBUS, OHIO OFFIC E DAYTON, OHIO OFFICE 513-381-2838 21 EAST STATE STREET 110S NU OR IT THEMA 9I0 N 0 STC RE O ET LF U AM X : 5B 13-38U 1-02S 05 , OHIO 43215-4221 DAYTON, OHIO 45402-1786 937-228-2838 www FAX: 937-228-2816 .taftlaw.com FAX614-221-2838 :614-221-2007 ROBERT A .

.

.